Wang, Lexington
Andrew Ming Wang, Lexington, MA US
Patent application number | Description | Published |
---|---|---|
20140195399 | METHOD AND SYSTEM FOR ACHIEVING POSITIVE NET PROFITS STATISTICALLY - This invention discloses an investment method for achieving consistent positive profits, positive net profits, or “absolute return”, statistically. It begins with evaluating a trading system. Average and standard deviation are calculated from occurred individual trading profits to estimate expected average profit and risk. Expected cumulative profits and cumulative standard deviations are then estimated from their corresponding individual counterparts. An expected performance map may be constructed with the expected cumulative profit and lower profit limit plots. To ensure positive net profits can be achieved, a high probability confidence level is specified, and a lower profit limit is estimated. If the expected average profit is positive, expected cumulative profits will continuously increase. After sufficient trades, the lower profit limit will also increase and eventually become positive. Whereby, positive net profits can be achieved with high probability, while risk is limited by the lower profit limit. Thus risk occurs at a low probability. | 07-10-2014 |
Changfeng Charles Wang, Lexington, MA US
Patent application number | Description | Published |
---|---|---|
20160055244 | Audience on Networked Devices - Methods, systems, and apparatus, including computer programs encoded on computer storage media, for an audience of network devices. One of the methods includes receiving information from a source, the information associated with a device identifier. The method includes determining, based on the device identifier, a unique user identifier, wherein the unique user identifier identifies a user independent of network, media, and location. The method includes identifying at least one user attribute based on the received information. The method includes associating the user attribute with the unique user identifier. The method also includes storing the user attribute in a repository. The repository stores a plurality of other user attributes associated with the unique user identifier, the other stored user attributes being received from a plurality of different sources. | 02-25-2016 |
20160086215 | Providing Data and Analysis for Advertising on Networked Devices - Methods, systems, and apparatus, including computer programs encoded on computer storage media, for providing data and analysis for advertising on networked devices. One of the methods includes creating a vector of identifiers representing an ad opportunity. The method includes linking data attributes that describe the ad opportunity to the identifiers. The method includes expressing the data attributes following predefined scheme of hierarchy. The method includes linking a taxonomy describing data attributes. The method includes obtaining outcome measurements of ad events associated with the ad opportunity. The method also includes associating user interaction events with the ad with at least one of the identifiers or data attributes associated with the identifier. | 03-24-2016 |
Chuan Wang, Lexington, MA US
Patent application number | Description | Published |
---|---|---|
20140195399 | METHOD AND SYSTEM FOR ACHIEVING POSITIVE NET PROFITS STATISTICALLY - This invention discloses an investment method for achieving consistent positive profits, positive net profits, or “absolute return”, statistically. It begins with evaluating a trading system. Average and standard deviation are calculated from occurred individual trading profits to estimate expected average profit and risk. Expected cumulative profits and cumulative standard deviations are then estimated from their corresponding individual counterparts. An expected performance map may be constructed with the expected cumulative profit and lower profit limit plots. To ensure positive net profits can be achieved, a high probability confidence level is specified, and a lower profit limit is estimated. If the expected average profit is positive, expected cumulative profits will continuously increase. After sufficient trades, the lower profit limit will also increase and eventually become positive. Whereby, positive net profits can be achieved with high probability, while risk is limited by the lower profit limit. Thus risk occurs at a low probability. | 07-10-2014 |
Dongxue Wang, Lexington, MA US
Patent application number | Description | Published |
---|---|---|
20130039029 | Light Engine Having Distributed Remote Phosphors - There is herein described a light engine that emits a light. The light engine includes a light source, a light guide, a plurality of extraction optical elements, and a plurality of phosphors. The light guide receives the light. The extraction optical elements are on the surface of the light guide. The extraction optical elements extract at least a portion of the light out of the light guide. The phosphors are disposed on top of at least some of the extraction optical elements. | 02-14-2013 |
Hongren Wang, Lexington, MA US
Patent application number | Description | Published |
---|---|---|
20130224293 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF - The present invention relates to pharmaceutical compositions containing a solid dispersion of N—[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition. | 08-29-2013 |
20140255483 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF - The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition. | 09-11-2014 |
20150024047 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF - The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition. | 01-22-2015 |
20150246031 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF - The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition. | 09-03-2015 |
Hui-Qin Wang, Lexington, MA US
Patent application number | Description | Published |
---|---|---|
20140275089 | 2-Carboxamide Cycloamino Urea Derivatives in Combination with HSP90 Inhibitors for the Treatment of Proliferative Diseases - The present invention relates to a pharmaceutical combination comprising a 2-carboxamide cycloamino urea derivative compound of formula (I) and inhibitors of Heat Shock Protein 90, and the uses of such combinations in the treatment of proliferative diseases, more specifically PI3K dependent diseases, more specifically PI3K-alpha dependent diseases. | 09-18-2014 |
20150216870 | Combination of PI3K Inhibitor and C-Met Inhibitor - The present invention relates to a pharmaceutical combination which comprises (a) a phosphatidylinositol 3-kinase inhibitor or pharmaceutically acceptable salt thereof, and (b) at least one c-Met receptor tyrosine kinase inhibitor or pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential administration for the treatment of a proliferative disease, particularly a c-Met dependent proliferative disease; a pharmaceutical composition comprising such combination; a method of treating a subject having a proliferative disease comprising administration of said combination to a subject in need thereof; use of such combination for the treatment of proliferative disease; and a commercial package comprising such combination. | 08-06-2015 |
20150290204 | COMBINATION THERAPY - A pharmaceutical combination comprising (a) a compound of formula (I), | 10-15-2015 |
Hwa-Tang Wang, Lexington, MA US
Patent application number | Description | Published |
---|---|---|
20130217010 | CONTAINERS FOR AGITATION OF LIQUID SAMPLES AND METHODS OF USE THEREOF - The present invention relates to containers for holding liquid samples. The containers may be useful for mixing a liquid sample or lysing cells in a liquid sample. The invention also relates to methods of using the containers of the invention. | 08-22-2013 |
Jack Wang, Lexington, MA US
Patent application number | Description | Published |
---|---|---|
20140187488 | METHODS FOR MAINTAINING PEGYLATION OF POLYPEPTIDES - Described herein are methods for maintaining PEGylation and inhibiting dePEGylation of polypeptides, such as fibronectin-based scaffold proteins, during storage. | 07-03-2014 |
Meng-Jiao Wang, Lexington, MA US
Patent application number | Description | Published |
---|---|---|
20110281046 | ELASTOMER COMPOSITE MATERIALS IN LOW DENSITY FORMS AND METHODS - A bale of elastomer composite is formed of elastomer and filler; the bale having a void volume of at least 3%. In another aspect, a container is provided, at least a portion of the container being occupied by elastomer composite pieces of elastomer and filler, wherein the occupied portion of the container has a void volume of at least 3%. | 11-17-2011 |
Thomas Wang, Lexington, MA US
Patent application number | Description | Published |
---|---|---|
20110311650 | MULTIPLEXED BIOMARKERS OF INSULIN RESISTANCE - The invention, in some aspects, relates to methods for characterizing glucose-related metabolic disorders. In some aspects, the invention relates to methods and kits useful for diagnosing, classifying, profiling, and treating glucose-related metabolic disorders. In some aspects, the invention relates to methods useful for diagnosing, classifying, profiling, and treating diabetes. | 12-22-2011 |
20120214821 | Lipidomic Biomarkers of Diabetes - The invention, in some aspects, relates to methods for predicting a subject's risk of developing a glucose-related metabolic disorder, e.g., diabetes. In some aspects, the invention relates to methods for selecting and monitoring a treatment for a glucose-related metabolic disorder, e.g., diabetes. | 08-23-2012 |
20160030373 | 2-AAA as a Biomarker and Therapeutic Agent for Diabetes - Methods for treating a glucose-related metabolic disorder (e.g., diabetes) comprising administration of 2-aminoadipic acid (2-AAA) to subjects in need thereof. Also described are methods for predicting a subject's risk of developing a glucose-related metabolic disorder, and to methods for selecting and monitoring a treatment for a glucose-related metabolic disorder (e.g., diabetes). | 02-04-2016 |
Thomas J. Wang, Lexington, MA US
Patent application number | Description | Published |
---|---|---|
20150133521 | INHIBITORS OF MICRORNAs THAT REGULATE PRODUCTION OF ATRIAL NATRIURETIC PEPTIDE (ANP) AS THERAPEUTICS AND USES THEREOF - The present invention relates to methods, kits and compositions to treat hypertension and other cardiovascular diseases in a subject, in particular, a method of treating or preventing a cardiovascular disease in a subject comprising administering to a subject at least one anti-miR agent to miRNA-425. In some embodiments, an anti-miR agent is a small molecule or an oligonucleotide complementary to at least part of the miR-425 of SEQ ID NO: 1, or an anti-miR complementary to at least part of the miRNA seed sequence AUGACA (SEQ ID NO: 2). Another aspect of the present invention relates to methods, kits and compositions to treat low blood pressure in a subject comprising administering a composition comprising a miR-425 agent to decrease ANP levels in the subject. Other aspects of the present invention relates to assays, methods and systems to identify a subject at risk of hypertension, or identifying a subject suitable to administration of an anti-miR-425 agent for treatment of hypertension, the assay comprising assessing if a subject is homozygous or heterozygous for the major (A) allele of rs5068 SNP, and/or assaying for levels of miR-425 and/or assaying for levels of NT-proANP and/or levels of ANP in the plasma of a subject. | 05-14-2015 |
Tien Yang Wang, Lexington, MA US
Patent application number | Description | Published |
---|---|---|
20130001611 | SEMICONDUCTOR LIGHT-EMITTING DEVICE AND METHOD OF MANUFACTURING THE SAME - A light-emitting device includes a light emitting structure comprising a lower layer of the first conductivity type, an active layer, an upper layer of the second conductivity type, a first electrode connected to the lower layer of the first conductivity type, a second electrode connected to the upper layer of the second conductivity type, and an optical member seeded in the light emitting structure. The optical member can include a plurality of particles substantially transparent and having a lower refractive index than the light emitting structure. A plurality of discontinuities are formed at the boundary of the optical member in the light emitting structure. | 01-03-2013 |
20140231841 | SEMICONDUCTOR LIGHT-EMITTING DEVICE AND METHOD OF MANUFACTURING THE SAME - A light-emitting device is disclosed including a light emitting structure comprising a lower layer of the first conductivity type, an active layer, an upper layer of the second conductivity type; a first electrode connected to the lower layer of the first conductivity type; a second electrode connected to the upper layer of the second conductivity type. The light emitting structure is formed using a shell member, which comprises a planar portion and a shell portion. The extent of growth defects such as misfit dislocations is reduced and the extraction of light and heat is improved in the present device. The beam profile of the device may be altered by patterning the light emitting structure instead of shaping the entire chip. The device may be manufactured in a way more compatible with the established, cost-effective processing and packaging methods for large size wafers from the IC industry. | 08-21-2014 |